Wuxi Biologics Cayman
WuXi Biologics (Cayman) Inc. is a China-based contract research, development, and manufacturing organization (CRDMO) focused on biologics. The company provides end-to-end biological drug discovery, process development, clinical trial supply, and commercial-scale manufacturing services. Its service offerings support the creation of monoclonal antibodies, antibody-drug conjugates (ADCs), and recombinant proteins for global biopharmaceutical companies. Revenue is derived from fee-for-service research contracts alongside milestone fees and commercial-scale production volume orders. WuXi Biologics maintains a leading global market position in outsourced biopharmaceutical development services. The company is headquartered in Wuxi, China, and its shares are listed on the Stock Exchange of Hong Kong.
29 of the funds FundTelligence covers report a position in Wuxi Biologics Cayman.
- Legal name
- Wuxi Biologics Cayman Inc
- Sector
- Health Care
- Country
- China
- Funds holding it
- 29
Funds holding Wuxi Biologics Cayman
- Templeton BIC Fund — Franklin Templeton · 3.14 % (full portfolio disclosed, September 2026)
- Templeton Global Smaller Companies Fund — Franklin Templeton · 3.03 % (full portfolio disclosed, September 2026)
- Allianz China Equity — Allianz Global Investors · 2.92 % (largest positions only, September 2026)
- Allianz All China Equity — Allianz Global Investors · 2.42 % (largest positions only, September 2026)
- Templeton Emerging Markets Fund — Franklin Templeton · 2.17 % (full portfolio disclosed, September 2026)
- Nordea Chinese Equity Fund — Nordea Funds · 1.53 % (full portfolio disclosed, September 2026)
- Nordea China — Nordea Funds · 1.52 % (full portfolio disclosed, September 2026)
- Templeton Asian Growth Fund — Franklin Templeton · 1.13 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 29 funds holding it.